Analyst Reco. Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
21.14 ^USD	+3.88%		-2.58%	+250.58%

May. 03	Wedbush Adjusts Longboard Pharmaceuticals' PT to $34 From $32, Keeps Outperform Rating	MT
May. 02	Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Adjusts Longboard Pharmaceuticals' PT to $34 From $32, Keeps Outperform Rating	May. 03	MT
Baird Starts Longboard Pharmaceuticals With Outperform Rating, $36 Price Target	May. 01	MT
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $60 From $55, Maintains Overweight Rating	Jan. 16	MT
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating	Jan. 12	MT
HC Wainwright Adjusts Price Target on Longboard Pharmaceuticals to $60 From $25, Keeps Buy Rating	Jan. 08	MT
Wedbush Raises Longboard Pharmaceuticals' PT to $32 From $22, Says Offering Removes Near-Term Cash Runway Overhang, Provides Resources to Advance Bexicaserin; Keeps Outperform Rating	Jan. 08	MT
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $55 From $35, Maintains Overweight Rating	Jan. 02	MT
Guggenheim Raises Longboard Pharmaceuticals' Price Target to $32 From $16, Keeps Buy Rating	Jan. 02	MT
Wedbush Raises Longboard Pharmaceuticals' PT to $22 From $11, Says PACIFIC Data Readout Provides Best-Case Scenario for Bexicaserin (LP352); Keeps Outperform Rating	Jan. 02	MT
Cantor Fitzgerald Adjusts Price Target on Longboard Pharmaceuticals to $16 From $11, Keeps Overweight Rating	23-05-11	MT
B. Riley Initiates Longboard Pharmaceuticals at Buy With $13 Price Target, Believes Shares Are Undervalued	23-04-27	MT
Citigroup Cuts Price Target on Longboard Pharmaceuticals to $17 From $24, Maintains Buy Rating	23-03-06	MT
Guggenheim Trims Price Target on Longboard Pharmaceuticals to $16 From $18, Maintains Buy Rating	22-11-11	MT
Wedbush Trims Longboard Pharmaceuticals' Price Target to $11 From $12, Keeps Outperform Rating	22-11-04	MT
Wedbush Cuts Price Target on Longboard Pharmaceuticals to $12 From $14 'on Lower Net Cash;' Outperform Rating Kept	22-05-06	MT
HC Wainwright Initiates Longboard Pharmaceuticals at Buy with $25 Price Target	22-04-27	MT
Wedbush Starts Longboard Pharmaceuticals at Outperform With $14 Price Target	22-02-14	MT
LONGBOARD PHARMACEUTICALS : Evercore ISI Starts Longboard Pharmaceuticals at Outperform with $35 Price Target	21-04-07	MT
LONGBOARD PHARMACEUTICALS : Citigroup Initiates Longboard Pharmaceuticals at Buy Rating With $37 Price Target	21-04-06	MT
LONGBOARD PHARMACEUTICALS : Cantor Fitzgerald Initiates Longboard Pharmaceuticals at Overweight Rating With $32 Price Target	21-04-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Analyst Reco.

Filters